Efficacy of autologous platelet-rich plasma for the treatment of muscle rupture with haematoma: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
The goals of the treatment of muscle injuries are to shorten the time of healing and to avoid relapses. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) in the healing of muscle injuries.



A multicentre, randomised, double-blind, parallel, controlled clinical trial was conducted in 71 patients (81.8% males) aged 45.6 (SD=10.0) years with muscle tears in the legs and haematoma. The haematoma was evacuated in all patients. Thirty-three patients were randomised to a single dose of autologous PRP and 38 patients to simulation of PRP administration. The primary end-point was time to complete recovery of muscle injury. Secondary end-points were pain, relapses, ultrasound parameters, and adverse events. The total follow-up per patient was 12 months.



Time to complete recovery after the treatment was 31.63 days (SD=15.38) in the PRP group, and 38.43 days (SD=18.58) in the control group (p=0.261). Pain decreased over time in both groups without statistical differences between them. Eight patients relapsed (seven in the control group, and one in the PRP group). There were no adverse effects related to the interventions.



Autologous PRP did not significantly improve the time to healing compared to that in the control group.
Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain.|CIBER of Epidemiology and Public Health, Barcelona, Spain.
Ma José
MJ
Martinez-Zapata
ITRT, Quirón-Teknon Hospital, Barcelona, Spain.
Lluís
L
Orozco
Sport Catalan Council, Generalitat de Catalunya, Barcelona, Spain.
Ramon
R
Balius
ITRT, Quirón-Teknon Hospital, Barcelona, Spain.
Robert
R
Soler
Blood and Tissue Bank of Catalonia, Barcelona, Spain.
Alba
A
Bosch
Medical Services, Barcelona Football Club, Barcelona, Spain.
Gil
G
Rodas
Medical Services, Barcelona Football Club, Barcelona, Spain.|High Performance Centre, Health Consortium of Terrassa, Barcelona, Spain.
Lluís
L
Til
Vithas Montserrat Hospital, Catalunya National Institute of Physical Education, Lleida, Spain.
Xavier
X
Peirau
Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain.|CIBER of Epidemiology and Public Health, Barcelona, Spain.
Gerard
G
Urrútia
CIBER of Epidemiology and Public Health, Barcelona, Spain.|Clinical Epidemiology and Public Health Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Ignasi
I
Gich
Iberoamerican Cochrane Centre, IIB Sant Pau, Barcelona, Spain.|CIBER of Epidemiology and Public Health, Barcelona, Spain.|Clinical Epidemiology and Public Health Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Xavier
X
Bonfill
D004311:Double-Blind Method; D006406:Hematoma; D006801:Humans; D017713:Platelet Transfusion; D053657:Platelet-Rich Plasma; D052256:Tendinopathy / Q000628:therapy; D016896:Treatment Outcome